Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Exicure","sponsor":"Ipsen","pharmaFlowCategory":"D","amount":"$1,020.0 million","upfrontCash":"$20.0 million","newsHeadline":"ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Discovery","country":"IRELAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Exicure"}]

Exicure

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders

Details:

Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome.

Lead Product(s): SNA-based Therapeutics

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Ipsen

Deal Size: $1,020.0 million Upfront Cash: $20.0 million

Deal Type: Collaboration August 02, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY